Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Non Operating Income: 2023-2025

Historic Non Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to $4.5 million.

  • Day One Biopharmaceuticals' Non Operating Income fell 30.59% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.3 million, marking a year-over-year decrease of 84.09%. This contributed to the annual value of $128.9 million for FY2024, which is 651.84% up from last year.
  • Day One Biopharmaceuticals' Non Operating Income amounted to $4.5 million in Q3 2025, which was down 2.73% from $4.7 million recorded in Q2 2025.
  • In the past 5 years, Day One Biopharmaceuticals' Non Operating Income registered a high of $112.0 million during Q2 2024, and its lowest value of $3.5 million during Q2 2023.
  • Moreover, its 3-year median value for Non Operating Income was $5.0 million (2023), whereas its average is $15.7 million.
  • As far as peak fluctuations go, Day One Biopharmaceuticals' Non Operating Income surged by 3,133.74% in 2024, and later crashed by 95.84% in 2025.
  • Over the past 3 years, Day One Biopharmaceuticals' Non Operating Income (Quarterly) stood at $5.0 million in 2023, then rose by 21.69% to $6.1 million in 2024, then tumbled by 30.59% to $4.5 million in 2025.
  • Its Non Operating Income stands at $4.5 million for Q3 2025, versus $4.7 million for Q2 2025 and $5.1 million for Q1 2025.